KYTX: Kyverna Price to Sales

Brandmark of Kyverna Therapeutics Inc. (KYTX)

Kyverna Therapeutics (KYTX) delegates production and testing to external partners to maintain scientific flexibility. The price-to-sales ratio reflects the market valuation dynamics, where represents the latest level. Innovative CAR-T technologies enable the radical treatment of sclerosis and lupus, generating immense interest from clinics due to the shortcomings of traditional therapy methods.

Market Cap to Revenue: Kyverna (KYTX) for 07/04/2022 - 11/17/2026

Analytical breakdowns for Kyverna Therapeutics Inc. (KYTX)

Fundamental company analysis:Kyverna Therapeutics Inc., KYTX
Product sample of Kyverna Therapeutics, Inc.

By outsourcing production and testing, Kyverna Therapeutics (KYTX) maintains flexibility, which is reflected in the price/sales multiple trend. This indicator compares the total market value of the business with its annual sales volume, determining the price of one dollar of revenue. The upward trend signals market optimism, yet simultaneously increases the risk of a correction should the economic cycle slow down.

Competitors of Kyverna Therapeutics

argenx - Market Cap to Revenue Ratio|P/S Multiple BNTX (biontech.de)|Abivax Corp (ABVX) - Price to Sales|ADMA Corp - P/S Multiple|Price-to-Sales Ratio PTGX|Immunovant Inc (IMVT) - Price-to-Revenue Ratio|KNSA - Price-to-Revenue Coefficient|GRFS (Grifols Biemat) - P/S Multiple|P/S Multiple Adaptive Biotechnologies Inc.|Price-to-Revenue Ratio Celldex Therapeutics (CLDX)|Price-to-Revenue Coefficient auriniapharma.com|Price-to-Revenue Ratio BioCryst Pharmaceuticals BCRX|Market Capitalization-to-Revenue Ratio VERA|Dianthus Pharma - P/S Multiple|PHVS - P/S Multiple|ABCL: P/S Multiple|TRML (Tourmaline Bio, Inc.) - Price-to-Revenue Ratio|Price-to-Revenue Ratio Intrexon|PHAR - Price-to-Revenue Multiple|P/S Multiple NKTR|Price-to-Revenue Ratio UPB (Upstream Bio Corp)|Price-to-Revenue Ratio Zenas Biopharma, Inc. ZBIO|Price-to-Revenue Coefficient immunome.com (IMNM)|Gossamer Bio Inc - P/S Multiple|Market Capitalization-to-Revenue Ratio KALV (KalVista Pharmaceuticals, Inc.)|SEPN: P/S Multiple|Market Cap to Revenue Pieris Pharmaceuticals Inc|Market Cap to Revenue SVRA|Market Cap to Revenue Rigel Pharmaceuticals (RIGL)|P/S Multiple ANAB|ATXS - Price to Sales|Price-to-Revenue Ratio enGene Corp ENGN|Price-to-Revenue Coefficient RAPT Therapeutics, Inc. (RAPT)|Aerovate - P/S Multiple|ACRS - P/S Multiple|TLSA: P/S Multiple|Market Cap to Revenue Cabaletta Bio, Inc|Price-to-Revenue Ratio Ventyx Biosciences, Inc|THTX: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue AVTX (Avalo Therapeutics, Inc)|Market Cap to Revenue Eledon Pharmaceuticals ELDN|Price-to-Revenue Ratio Agenus, Inc. AGEN|P/S Multiple Climb Bio Inc. CLYM|ZURA - Price-to-Revenue Ratio|Price-to-Sales Ratio ATYR|ADAG (Adagene Inc.) - Market Cap to Revenue|ImageneBio Inc (IMA) - P/S Multiple|Price-to-Revenue Ratio Shattuck Therapeutics|Market Cap to Revenue equilliumbio.com (EQ)|P/S Multiple CNTB|Price-to-Revenue Coefficient Immunic Therapeutics|P/S Multiple ATRA (Atara Biotherapeutics, Inc.)|IFRX - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio X4 Pharmaceuticals, Inc. (XFOR)|ACET (adicetbio.com) - Market Cap to Revenue Ratio|CELU: P/S Multiple|INMB - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Barinthus Biotherapeutics plc|KZR: Market Capitalization-to-Revenue Ratio|P/S Multiple SABS|AKTX (Akari Therapeutics Plc) - Market Capitalization-to-Revenue Ratio|P/S Multiple ENLV (Enlivex Therapeutics Ltd)|q32bio.com - Price-to-Revenue Ratio|GOVX: Market Cap to Revenue|edesabiotech.com (EDSA) - Market Cap to Revenue|IBIO: P/S Multiple|CARM - Price-to-Revenue Coefficient|Market Cap to Revenue XTLB|Market Cap to Revenue boltbio.com (BOLT)|Price-to-Revenue Ratio HCW Biologics Inc (HCWB)|P/S Multiple Aptevo Therapeutics, Inc. (APVO)|Price-to-Revenue Ratio aimimmuno.com AIM|Market Capitalization-to-Revenue Ratio ADTX|GRI Bio Corporation - P/S Multiple|XORTX Corp (XRTX) - Market Cap to Revenue|HIND (Vyome Holdings Inc.) - Market Cap to Revenue|revbiosciences.com (REVB) - P/S Multiple|INDP (Indaptus Corp) - P/S Multiple|Market Cap to Revenue Scinai Immunotherapeutics Ltd (SCNI)|Price-to-Revenue Ratio CalciMedica Inc (CALI)|AFMD (Affimed NV) - Market Capitalization-to-Revenue Ratio|P/S Multiple ALLK (Allakos Inc.)|P/S Multiple HOOKIPA HOOK|IGMS: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ITOS (iTeos)|OCEA: P/S Multiple|TCBP (TC BioPharm Ltd) - Price-to-Revenue Ratio|THRD (Third Harmonic Bio Inc) - P/S Multiple